MediPharm Labs Corp.

TSX:LABS 주식 보고서

시가총액: CA$30.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MediPharm Labs 미래 성장

Future 기준 확인 2/6

MediPharm Labs은 연간 수입과 매출이 각각 67.2%와 22.7% 증가할 것으로 예상되고 EPS는 연간 64%만큼 증가할 것으로 예상됩니다.

주요 정보

67.2%

수익 성장률

64.0%

EPS 성장률

Pharmaceuticals 수익 성장70.9%
매출 성장률22.7%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트17 May 2024

최근 미래 성장 업데이트

Recent updates

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29
MediPharm Labs (TSE:LABS) Is Using Debt Safely

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11
Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

수익 및 매출 성장 예측

TSX:LABS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CAD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202555-3N/AN/A2
12/31/202444-9N/AN/A2
3/31/202437-14-11-11N/A
12/31/202333-13-13-12N/A
9/30/202330-16-15-14N/A
6/30/202328-19-14-14N/A
3/31/202323-26-14-14N/A
12/31/202222-30-17-16N/A
9/30/202222-46-21-20N/A
6/30/202220-46-18-17N/A
3/31/202221-48-13-13N/A
12/31/202122-55-14-13N/A
9/30/202122-64-17-16N/A
6/30/202122-72-27-26N/A
3/31/202130-63-33-28N/A
12/31/202036-66-45-38N/A
9/30/202062-39-46-29N/A
6/30/2020101-20-67-40N/A
3/31/2020118-15-74-45N/A
12/31/20191292-58-25N/A
9/30/20191071-54-27N/A
6/30/201964-4-36-12N/A
3/31/201932-8-23-4N/A
12/31/201810-8-26-11N/A
9/30/2018N/A-6-23-10N/A
6/30/2018N/A-4-9-4N/A
3/31/2018N/A-2-7-3N/A
12/31/2017N/A-1N/A0N/A

애널리스트 미래 성장 예측

수입 대 저축률: LABS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: LABS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: LABS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: LABS 의 수익(연간 22.7% ) Canadian 시장( 7.3% 보다 빠르게 성장할 것으로 예상됩니다. 7.3% 연간).

고성장 수익: LABS 의 수익(연간 22.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: LABS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견